MorphoSys AG (MOR)
19.37
+0.87
(+4.70%)
USD |
NASDAQ |
May 16, 16:00
19.37
0.00 (0.00%)
After-Hours: 20:00
MorphoSys Cash from Financing (Quarterly)
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2023 | -5.840M |
| March 31, 2023 | -48.68M |
| June 30, 2022 | 1.286M |
| March 31, 2022 | 15.46M |
| December 31, 2021 | 12.44M |
| September 30, 2021 | 1.519B |
| June 30, 2021 | 20.29M |
| March 31, 2021 | 13.29M |
| December 31, 2020 | 361.50M |
| September 30, 2020 | 39.22M |
| June 30, 2020 | 635.31M |
| March 31, 2020 | |
| December 31, 2019 | -0.0598M |
| September 30, 2019 | 2.253M |
| June 30, 2019 | -0.8259M |
| March 31, 2019 | -0.9718M |
| December 31, 2018 | 3.085M |
| September 30, 2018 | -4.434M |
| June 30, 2018 | 213.26M |
| March 31, 2018 | 0.00 |
| December 31, 2017 | 2.415M |
| September 30, 2017 | 1.116M |
| June 30, 2017 | 5.725M |
| March 31, 2017 | |
| December 31, 2016 | 124.63M |
| Date | Value |
|---|---|
| September 30, 2016 | 0.0298M |
| June 30, 2016 | -0.0595M |
| March 31, 2016 | -2.408M |
| December 31, 2015 | 1.071M |
| September 30, 2015 | 0.1413M |
| June 30, 2015 | -5.836M |
| March 31, 2015 | 0.1114M |
| December 31, 2014 | 1.394M |
| September 30, 2014 | 0.6711M |
| June 30, 2014 | 3.455M |
| March 31, 2014 | -10.73M |
| December 31, 2013 | 2.086M |
| September 30, 2013 | 174.35M |
| June 30, 2013 | -2.950M |
| March 31, 2013 | 0.00 |
| December 31, 2012 | 0.8839M |
| September 30, 2012 | 0.9137M |
| June 30, 2012 | -0.5281M |
| March 31, 2012 | 0.7959M |
| December 31, 2011 | 1.089M |
| September 30, 2011 | 0.2843M |
| June 30, 2011 | -0.5249M |
| March 31, 2011 | 0.9962M |
| December 31, 2010 | 2.108M |
| September 30, 2010 | 1.697M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-48.68M
Minimum
Mar 2023
1.519B
Maximum
Sep 2021
183.21M
Average
12.86M
Median
Cash from Financing (Quarterly) Benchmarks
| Novartis AG | -5.164B |
| Immatics NV | -1.580M |
| Affimed NV | -1.482M |
| InflaRx NV | -0.0931M |
| BioNTech SE | -8.472M |
Cash from Financing (Quarterly) Related Metrics
| Free Cash Flow Yield | -17.83% |